Karyopharm Therapeutics Inc. — fact timeline

Karyopharm Therapeutics Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-05-21 meeting.

“5. The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the stockholders’ vote with respect to such ratification were as follows: Votes For Votes Against Votes Abstaining 16,695,588 86,550 59,428”

Karyopharm Therapeutics Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2026-05-21 meeting.

“4. The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. The results of the stockholders’ vote with respect to such approval were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 10,025,198 1,388,274 17,213 5,410,881”

Karyopharm Therapeutics Inc. shareholders approved Amendment to the Karyopharm Therapeutics Inc. Amended & Restated 2013 Employee Stock Purchase Plan to increase shares available by 1,400,000 at the 2026-05-21 meeting.

“3. The Company’s stockholders approved an amendment to the Karyopharm Therapeutics Inc. Amended & Restated 2013 Employee Stock Purchase Plan, as amended, to increase the number of shares of the Company’s common stock available for issuance thereunder by 1,400,000 shares. The results of the stockholders’ vote with respect to such approval were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 11,221,920 203,702 5,063 5,410,881”

Karyopharm Therapeutics Inc. shareholders approved Amendment to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan to increase shares available by 3,000,000 at the 2026-05-21 meeting.

“2. The Company’s stockholders approved an amendment to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended, to increase the number of shares of the Company’s common stock available for issuance there under by 3,000,000 shares. The results of the stockholders’ vote with respect to such approval were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 10,474,681 953,411 2,593 5,410,881”

Karyopharm Therapeutics Inc. shareholders approved Election of Barry E. Greene and Christy J. Oliger as Class I directors at the 2026-05-21 meeting.

“1. The Company’s stockholders elected Barry E. Greene and Christy J. Oliger as Class I directors, each to serve on the Board for a three-year term until the 2029 annual meeting of stockholders and until his or her resignation or removal or until his or her successor is duly elected and qualified. The results of the stockholders’ vote with respect to the election of such Class I directors were as follows: Votes For Votes Withheld Broker Non-Votes Barry E. Greene 8,961,538 2,469,147 5,410,881 Christy J. Oliger 10,601,387 829,298 5,410,881”

Karyopharm Therapeutics Inc. reported Full-Year 2026 results: revenue Company Reaffirms Full-Year 2026 Total Revenue Guidance of $130 Million to $150 Million Including U.S. XPOVIO Net Produc. Guidance reaffirmed.

“Company Reaffirms Full-Year 2026 Total Revenue Guidance of $130 Million to $150 Million Including U.S. XPOVIO Net Product Revenue Guidance of $115 Million to $130 Million”

Karyopharm Therapeutics Inc. reported first quarter of 2026 results: revenue Total Revenue was $35.1 Million. Guidance reaffirmed.

“Total Revenue was $35.1 Million and U.S. XPOVIO® (selinexor) Net Product Revenue was $29.2 Million for the First Quarter of 2026”

Karyopharm Therapeutics Inc. issued accompanying warrants to purchase 4,421,518 shares of Common Stock of warrant to RA Capital Management.

“(ii) accompanying warrants to purchase 4,421,518 shares of Common Stock with an exercise price of $10.00 per share (the “Common Stock Warrants”)”

Karyopharm Therapeutics Inc. issued pre-funded warrants to purchase up to 3,391,164 shares of Common Stock of warrant to RA Capital Management for $6.7849 per pre-funded warrant.

“in lieu of Common Stock, pre-funded warrants to purchase up to 3,391,164 shares of Common Stock (the “Pre-Funded Warrants”) at a purchase price of $6.7849 per pre-funded warrant”

Karyopharm Therapeutics Inc. issued 1,030,354 shares of common stock to RA Capital Management for $6.785 per share.

“the Company agreed to issue and sell (i) 1,030,354 shares (the “Shares”) of its common stock, par value $0.0001 per share (“Common Stock”), at a purchase price of $6.785 per share”

Karyopharm Therapeutics Inc. entered into Securities Purchase Agreement with RA Capital Management valued at gross proceeds of approximately $30 million (effective 2026-03-24).

“On March 24, 2026, Karyopharm Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with RA Capital Management (the “Investor”), pursuant to which the Company agreed to issue and sell (i) 1,030,354 shares (the “Shares”) of its common stock, par value $0.0001 per share (“Common Stock”), at a purchase price of $6.785 per share and, in lieu of Common Stock, pre-funded warrants to purchase up to 3,391,164 shares of Common Stock (the “Pre-Funded Warrants”) at a purchase price of $6.7849 per pre-funded warrant, and (ii) accompanying warrants to purchase 4,421,518 shares of Common Stock with an exercise price of $10.00 per share (the “Common Stock Warrants”) to the Investor in a private placement (collectively, the “Private Placement”).”

Karyopharm Therapeutics Inc. amended Second Amendment to Credit and Guaranty Agreement with Wilmington Savings Fund Society, FSB, as administrative agent and collateral agent (effective 2026-02-27).

“On February 27, 2026, Karyopharm Therapeutics Inc. (the “Company”) entered into the Second Amendment to Credit and Guaranty Agreement (the “Amendment”) with the lenders party thereto and Wilmington Savings Fund Society, FSB, as administrative agent and collateral agent”

Karyopharm Therapeutics Inc. incurred credit facility of $12.5 million with term loan lenders at not specified maturing not specified.

“On the Closing Date and as disclosed in the Current Report on Form 8-K filed by the Company on October 8, 2025, the Company borrowed $12.5 million under its credit and guaranty agreement, as amended, by the First Amendment and Waiver to Credit and Guaranty Agreement dated as of October 7, 2025.”

Karyopharm Therapeutics Inc. incurred convertible notes of $15.0 million aggregate principal amount of 9.00% senior secured convertible notes due 2028 and $103.5 million aggregate with holders of convertible notes and other investors at 9.00% maturing 2028 and 2029.

“On the Closing Date and as disclosed in the Current Report on Form 8-K filed by the Company on October 8, 2025, the Company issued $15.0 million aggregate principal amount of 9.00% senior secured convertible notes due 2028 and $103.5 million aggregate principal amount of 9.00% senior secured convertible notes due 2029.”

Karyopharm Therapeutics Inc. issued shares of common stock and warrants to purchase shares of common stock of common stock to holders of convertible notes for $24.25 million aggregate principal amount of the Company’s convertible notes due October 15, 2025.

“an exchange of $24.25 million aggregate principal amount of the Company’s convertible notes due October 15, 2025 for shares of common stock and warrants to purchase shares of common stock”

Karyopharm Therapeutics Inc. issued shares of common stock of common stock to holders of convertible notes for $15.0 million aggregate principal amount of the Company’s convertible notes due 2029.

“an exchange of $15.0 million aggregate principal amount of the Company’s convertible notes due 2029 for shares of common stock”

Karyopharm Therapeutics Inc. issued newly issued warrants to purchase an aggregate of 5,918,358 shares of common stock with an exercise price of $6.64 per share of warrant to accredited investors for $8.75 million.

“common stock and warrants to purchase shares of common stock; and (iv) a private placement of shares of common stock and warrants to purchase common stock for gross proceeds of $8.75 million. The Company intends to use the proceeds described above to pay transaction expenses and for general corporate purposes, including to support the Company’s ongoing and planned”

Karyopharm Therapeutics Inc. issued newly issued pre-funded warrants to purchase an aggregate of 2,913,136 shares of common stock of warrant to accredited investors for $8.75 million.

“common stock and warrants to purchase shares of common stock; and (iv) a private placement of shares of common stock and warrants to purchase common stock for gross proceeds of $8.75 million. The Company intends to use the proceeds described above to pay transaction expenses and for general corporate purposes, including to support the Company’s ongoing and planned”

Karyopharm Therapeutics Inc. issued 7,223,982 newly issued shares of common stock of common stock to accredited investors for $8.75 million.

“common stock and warrants to purchase shares of common stock; and (iv) a private placement of shares of common stock and warrants to purchase common stock for gross proceeds of $8.75 million. The Company intends to use the proceeds described above to pay transaction expenses and for general corporate purposes, including to support the Company’s ongoing and planned”

Karyopharm Therapeutics Inc.: Filed Certificate of Amendment to Restated Certificate of Incorporation to effect a 1-for-15 reverse stock split and proportionately reduce authorized shares of Common Stock (effective 2025-02-25).

“On February 24, 2025, Karyopharm Therapeutics Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation, as amended, (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware, which will effect, as of 5:00 p.m. Eastern Time, on February 25, 2025 (the “Effective Time”), a 1-for-15 reverse stock split (the “Reverse Stock Split”) of the issued and outstanding shares of the Company’s Common Stock, $0.0001 par value per share (the “Common Stock”).”

Kristin Abate was appointed as Vice President, Chief Accounting Officer at Karyopharm Therapeutics Inc..

“On November 20, 2024, Karyopharm Therapeutics Inc. (the “Company”) announced the appointment of Kristin Abate, the Company’s Vice President, Accounting, Corporate Controller and Assistant Treasurer, as the Company’s Vice President, Chief Accounting Officer, and Assistant Treasurer, effective November 20, 2024.”

Michael Mason resigned as Executive Vice President, Chief Financial Officer and Treasurer at Karyopharm Therapeutics Inc..

“On August 26, 2024, Michael Mason notified Karyopharm Therapeutics Inc. (the “Company”) of his intention to resign as the Company’s Executive Vice President, Chief Financial Officer and Treasurer to pursue other professional interests.”

Karyopharm Therapeutics Inc. incurred convertible notes of approximately $111.0 million aggregate principal amount of the Company’s new secured convertible senior notes.

“approximately $111.0 million aggregate principal amount of the Company’s new secured convertible senior notes”

Karyopharm Therapeutics Inc. incurred term loan of $100.0 million with Wilmington Savings Fund Society, FSB, as the administrative agent and collateral agent for the Lenders at Term SOFR (subject to a floor of 3.00%) plus 9.25% per annum maturing May 8, 2028.

“The Credit Agreement provides for a senior secured term loan facility of $100.0 million (the “Term Loan”).”

Karyopharm Therapeutics Inc. entered into Exchange Agreements with a limited number of existing holders of 2025 Notes who are institutional accredited investors and qualified institutional buyers valued at approximately $148.0 million aggregate principal amount (effective 2024-05-08).

“On the Closing Date, the Company also entered into privately-negotiated agreements (the “Exchange Agreements”) with a limited number of existing holders of 2025 Notes who are both institutional “accredited investors” (within the meaning of Rule 501(a)(1), (2), (3) or (7) promulgated under the Securities Act of 1933, as amended (the “Securities Act”)) and “qualified institutional buyers” (as defined in Rule 144A under the Securities Act) (such existing holders, the “Exchange Participants”) to exchange approximately $148.0 million aggregate principal amount of the Exchange Participants’ existing 2025”

Karyopharm Therapeutics Inc. entered into Credit Agreement with the lenders party thereto, and Wilmington Savings Fund Society, FSB, as administrative agent and collateral agent valued at $100.0 million (effective 2024-05-08).

“On May 8, 2024 (the “Closing Date”), the Company entered into a credit and guaranty agreement (the “Credit Agreement”) with the guarantors party thereto, the lenders party thereto (the “Lenders”), and Wilmington Savings Fund Society, FSB, as the administrative agent and collateral agent for the Lenders (in such capacity, the “Term Loan Agent”). The Credit Agreement provides for a senior secured term loan facility of $100.0 million (the “Term Loan”).”

Karyopharm Therapeutics Inc. reported the quarter ended March 31, 2024 results: revenue $33.1 million. Guidance reaffirmed.

“Readouts and Potential Approvals from the Company’s Three Phase 3 Trials, Strengthening the Company for its Next Stage of Growth – – Achieves First Quarter 2024 Total Revenue of $33.1 Million and U.S. XPOVIO ® (selinexor) Net Product Revenue of $26.0 Million – – Reaffirms Full Year 2024 Total Revenue Guidance of $140.0 Million to $160.0 Million, Including U.S. XPOVIO”

Karyopharm Therapeutics Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue Total Revenue of $146 Million. Guidance reaffirmed.

“Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress – Total Revenue of $146 Million and U.S. XPOVIO ® (selinexor) Net Product Revenue of $112 Million for Full Year 2023, Meeting Company’s Guidance”

Karyopharm Therapeutics Inc. reported fourth quarter and full year 2023 results: revenue approximately $146 million.

“Endometrial Cancer and Myelofibrosis – – Preliminary Unaudited Full Year 2023 Total Revenue and U.S. XPOVIO ® (selinexor) Net Product Revenue Expected to be Approximately $146 Million and $112 Million, Respectively, Meeting Company’s Guidance – – Potential for Selinexor to be a Novel Maintenance Treatment for Patients with TP53 Wild-Type Endometrial Cancer”

Karyopharm Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A), 5810(c)(3)(H)).

“December 6, 2023, Karyopharm Therapeutics Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Rule”). The deficiency letter does not result in the immediate delisting of the Company’s common stock from the Nasdaq Glo”

Peter K Honig resigned as member of the Board of Directors at Karyopharm Therapeutics Inc..

“On December 5, 2023, Peter K Honig, M.D., MPH, a member of the Board of Directors (the “Board”) of Karyopharm Therapeutics Inc. (the “Company”), notified the Company of his resignation from the Board, effective as of December 31, 2023.”

Karyopharm Therapeutics Inc. reported the quarter ended September 30, 2023 results: revenue $36.0 million. Guidance reaffirmed.

“Total revenue for the third quarter of 2023 was $36.0 million, compared to $36.1 million for the third quarter of 2022.”

Zhen Su was elected as Independent Director at Karyopharm Therapeutics Inc..

“elected Zhen Su, M.D., M.B.A, as an independent director of the Company to fill the newly created vacancy.”

Karyopharm Therapeutics Inc. reported the quarter ended June 30, 2023 results: revenue $37.6 Million. Guidance reaffirmed.

“Karyopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress – Achieved Second Quarter 2023 Total Revenue of $37.6 Million”

Karyopharm Therapeutics Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-12-31 meeting.

“7. The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”

Karyopharm Therapeutics Inc. shareholders approved Advisory vote on the compensation of the Company's named executive officers as disclosed in the Proxy Statement.

“6. The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.”

Karyopharm Therapeutics Inc. shareholders approved Approval of an amendment to the Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation (Officer Exculpation Amendment).

“5. The Company’s stockholders approved an amendment to the Company’s Restated Certificate of Incorporation, as amended, to reflect new Delaware law provisions regarding officer exculpation (the “Officer Exculpation Amendment”).”

Karyopharm Therapeutics Inc. shareholders approved Approval of an amendment to the Restated Certificate of Incorporation to increase authorized common stock from 200,000,000 to 400,000,000 shares (Share Increase Amendment).

“4. The Company’s stockholders approved an amendment to the Company’s Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of the Company’s common stock from 200,000,000 to 400,000,000 (the “Share Increase Amendment”).”

Karyopharm Therapeutics Inc. shareholders approved Approval of the Amended and Restated ESPP.

“3. The Company’s stockholders approved the Amended and Restated ESPP.”

Karyopharm Therapeutics Inc. shareholders approved Approval of 2022 Plan Amendment to increase shares available for issuance under the 2022 Plan by 5,000,000 shares.

“2. The Company’s stockholders approved the 2022 Plan Amendment to increase the number of shares of the Company’s common stock available for issuance under the 2022 Plan by 5,000,000 shares.”

Karyopharm Therapeutics Inc. shareholders approved Election of Barry E. Greene, Mansoor Raza Mirza M.D. and Christy J. Oliger as Class I directors.

“1. The Company’s stockholders elected Barry E. Greene, Mansoor Raza Mirza M.D. and Christy J. Oliger as Class I directors, each to serve on the Board for a three-year term until the 2026 annual meeting of stockholders and until his or her resignation or removal or until his or her successor is duly elected and qualified.”

Karyopharm Therapeutics Inc. reported Full Year 2023 results: revenue $145 Million to $160 Million. Guidance lowered.

“Company Revises Full Year 2023 Total Revenue Guidance to $145 Million to $160 Million, Including Revised XPOVIO Net Product Revenue Guidance of $110 Million to $125 Million, Reflecting Increased Use of PAP – – Non-GAAP R&D and SG&A Expense Guidance Revised to $245 Million to $260 Million; Company Re-iterates Cash Runway to Late 2025”

Karyopharm Therapeutics Inc. reported First Quarter 2023 results: revenue $38.7 Million.

“Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress – Achieved First Quarter 2023 Total Revenues of $38.7 Million, including XPOVIO ® (selinexor) Net Product Revenue of $28.3 Million, Adversely Impacted by Increased Utilization of Patient Assistant Programs (PAP) and Higher Gross to Net; YoY Growth in Total Demand 1”

Karyopharm Therapeutics Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue Total revenue for the fourth quarter of 2022 was $33.6 million, compared to $126.3 million for the fourth quarter of 202. Guidance initiated.

“On February 15, 2023, Karyopharm Therapeutics Inc. announced its financial results for the fourth quarter and full year ended December 31, 2022 and will conduct a previously announced, publicly available conference call to discuss those results and other company updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.”

Karyopharm Therapeutics Inc. reported fourth quarter and full year 2022 results: revenue approximately $34.2 million for the fourth quarter 2022 and approximately $157.7 million for the full year 2022.

“On January 9, 2023, Karyopharm Therapeutics Inc. (the “Company”) announced preliminary unaudited fourth quarter and full year 2022 total revenue and U.S. XPOVIO ® (selinexor) net product revenue estimates, and outlined its 2022 achievements and 2023 objectives.”

Karyopharm Therapeutics Inc. entered into Securities Purchase Agreement with certain institutional investors valued at approximately $165 million (effective 2022-12-05).

“On December 5, 2022, Karyopharm Therapeutics Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain institutional investors (the “ Purchasers ”), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement an aggregate of (i) 31,791,908 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) and (ii) accompanying warrants (the “ Warrants ”) to purchase up to 9,537,563 shares of Common Stock (collectively, the “ Private Placement ”).”

Karyopharm Therapeutics Inc.: The Board approved and restated the Third Amended and Restated By-Laws, effective immediately, with amendments including elimination of stockholder list requirement during meetings, addressing remote meeting adjournment due to technical failure, and revising procedural mechanics for shareholder nomi (effective 2022-12-01).

“On December 1, 2022, the board of directors (the “Board”) of Karyopharm Therapeutics Inc. (the “Company”) approved an amendment and restatement of the Company’s Second Amended and Restated By-Laws, as amended (as so amended and restated, the “Third Amended and Restated By-Laws”), effective immediately.”

Karyopharm Therapeutics Inc. reported full year 2022 results: revenue $155 Million to $165 Million. Guidance reaffirmed.

“Company Re-Affirms Full Year 2022 XPOVIO Net Product Revenue Guidance of $120 Million to $130 Million, Total Revenue Guidance of $155 Million to $165 Million and Cash Runway into Early 2024”

Karyopharm Therapeutics Inc. reported the quarter ended September 30, 2022 results: revenue $36.1 Million. Guidance reaffirmed.

“Karyopharm Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress – Achieved Third Quarter 2022 Total Revenue of $36.1 Million”

Stuart Poulton changed role as Executive Vice President, Chief Development Officer at Karyopharm Therapeutics Inc..

“Stuart Poulton, who has served as the Company’s Senior Vice President, Strategy and Portfolio Management since February 2022, has been promoted to Executive Vice President, Chief Development Officer, effective July 27, 2022.”